Tanios Bekaii-Saab, MD
Dosing strategies and novel treatment regimens are 2 of many areas being explored in the colorectal cancer (CRC) eld, while paying close attention to molecular subgroups, explained Tanios Bekaii-Saab, MD.
State of the Science Summit,™ Bekaii-Saab, who chaired the meeting, outlined clinical trials that have defined the current landscape of mCRC and what research is underway.
OncLive: What is currently being discussed in refractory mCRC?
: These patients go through first and second- line therapies, and sometimes through third-line therapy. The question becomes, “What do we do for patients beyond second-line therapy?” Previously, we had very few options, if any, for these patients. Now we have 2 oral options with regorafenib and TAS-102 (Lonsurf). These agents are different from each other. Regorafenib is a multikinase inhibitor; it’s a multitargeted agent. TAS-102 is a more traditional cytotoxic agent; it belongs to the family of fluoropyrimidines. It’s not 5-FU [5-fluorouracil] or capecitabine; it belongs to that family that seems to work when the others fail.
... to read the full story